Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
- Children affected by primary or secondary immunodeficiency at high risk of chronic COVID-19 [27];
- Children born with severe congenital heart disease at high risk of life-threatening cardiac complications [28];
- Children with neurological or neurocognitive problems in which persistent isolation may worsen psychological/psychiatric aspects [29].
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733. [Google Scholar] [CrossRef]
- Hui, D.S.; Azhar, E.I.; Madani, T.A.; Ntoumi, F.; Kock, R.; Dar, O.; Ippolito, G.; McHugh, T.D.; Memish, Z.A.; Drosten, C.; et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis. 2020, 91, 264–266. [Google Scholar] [CrossRef] [Green Version]
- World Health Organization. Coronavirus Disease 2019 (COVID-19). Situation Report–51. Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10 (accessed on 1 March 2020).
- Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020, 395, 565–574. [Google Scholar] [CrossRef] [Green Version]
- Garazzino, S.; Montagnani, C.; Donà, D.; Meini, A.; Felici, E.; Vergine, G. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Eurosurveillance 2020, 25, 2000600. [Google Scholar] [CrossRef]
- Ludvigsson, J.F. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020, 109, 1088–1095. [Google Scholar] [CrossRef]
- Florian Götzinger, F.; Santiago-García, B.; Noguera-Julián, A.; Lanaspa, M.; Lancella, L.; Calò Carducci, F.I. COVID-19 in children and adolescents in Europe: A multinational, multicentre cohort study. Lancet Child Adolesc. Health 2020, 4, 653–661. [Google Scholar] [CrossRef]
- Lu, X.; Zhang, L.; Du, H.; Zhang, J.; Li, Y.Y.; Qu, J.; Zhang, W.; Wang, Y.; Bao, S.; Li, Y.; et al. SARS-CoV-2 Infection in Children. N. Engl. J. Med. 2020, 382, 1663–1665. [Google Scholar] [CrossRef] [Green Version]
- Zachariah, P.; Johnson, C.L.; Halabi, K.C.; Ahn, D.; Sen, A.I.; Fischer, A.; Banker, S.L.; Giordano, M.; Manice, C.S.; Diamond, R.; et al. Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children’s Hospital in New York City, New York. JAMA Pediatr. 2020, 174, e202430. [Google Scholar] [CrossRef]
- Zimmermann, P.; Curtis, N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch. Dis. Child. 2020, 106, 429–439. [Google Scholar] [CrossRef]
- Romani, L.; Chiurchiù, S.; Santilli, V.; Bernardi, S.; Lombardi, M.H.; Scarselli, A.; Villani, A.; Degli Atti, M.L.C.; Campana, A.; D’Argenio, P. COVID-19 in Italian paediatric patients: The experience of a tertiary children’s hospital. Acta Paediatr. 2020, 109, 2311–2312. [Google Scholar] [CrossRef]
- Venturini, E.; Montagnani, C.; Garazzino, S.; Donà, D.; Pierantoni, L.; Vecchio, A.L.; Krzysztofiak, A.; Nicolini, G.; Bianchini, S.; Galli, L.; et al. Treatment of children with COVID-19: Update of the Italian Society of Pediatric Infectious Diseases position paper. Ital. J. Pediatr. 2021, 47, 139. [Google Scholar] [CrossRef] [PubMed]
- Andi, L.; Shane, A.L.; Sato, A.I.; Kao, C.; Adler-Shohet, F.C.; Vora, S.B.; Auletta, J.J. A Pediatric Infectious Diseases Perspective of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Novel Coronavirus Disease 2019 (COVID-19) in Children. J. Pediatr. Infect. Dis. Soc. 2020, 9, 596–608. [Google Scholar]
- Weinreich, D.M.; Sivapalasingam, S.; Norton, T. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med. 2021, 384, 238–251. [Google Scholar] [CrossRef] [PubMed]
- Razonable, R.R.; Pawlowski, C.; O’Horo, J.C.; Arndt, L.L.; Arndt, R.; Bierle, D.M.; Borgen, M.D.; Hanson, S.N.; Hedin, M.C.; Lenehan, P.; et al. Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. eClinicalMedicine 2021, 40, 101102. [Google Scholar] [CrossRef]
- Gottlieb, R.L.; Nirula, A.; Chen, P.; Boscia, J.; Heller, B.; Morris, J.; Huhn, G.; Cardona, J.; Mocherla, B.; Stosor, V.; et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19. JAMA 2021, 325, 632–644. [Google Scholar] [CrossRef]
- Dougan, M.; Nirula, A.; Azizad, M.; Mocherla, B.; Gottlieb, R.L.; Chen, P.; Hebert, C.; Perry, R.; Boscia, J.; Heller, B.; et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N. Engl. J. Med. 2021, 385, 1382–1392. [Google Scholar] [CrossRef] [PubMed]
- Gupta, A.; Gonzalez-Rojas, Y.; Juarez, E.; Casal, M.C.; Moya, J.; Falci, D.R.; Sarkis, E.; Solis, J.; Zheng, H.; Scott, N.; et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N. Engl. J. Med. 2021, 385, 1941–1950. [Google Scholar] [CrossRef]
- Sanyaolu, A.; Okorie, C.; Marinkovic, A.; Haider, N.; Abbasi, A.F.; Jaferi, U.; Prakash, S.; Balendra, V. The emerging SARS-CoV-2 variants of concern. Ther. Adv. Infect. Dis. 2021, 8, 20499361211024372. [Google Scholar] [CrossRef]
- Wolf, J.; Abzug, M.J.; Wattier, R.L.; Sue, P.K.; Vora, S.B.; Zachariah, P.; Dulek, D.E.; Waghmare, A.; Olivero, R.; Downes, K.J.; et al. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents. J. Pediatr. Infect. Dis. Soc. 2021, 10, 629–634. [Google Scholar] [CrossRef]
- Mak, G.; Dassner, A.M.; Hammer, B.M.; Hanisch, B.R. Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients. Pediatr. Infect. Dis. J. 2021, 40, e507–e509. [Google Scholar] [CrossRef]
- Uso Degli Anticorpi Monoclonali Per COVID-19|Agenzia Italiana Del Farmaco. Available online: https://www.aifa.gov.it/uso-degli-anticorpi-monoclonali (accessed on 14 June 2021).
- Management Strategies in Children and Adolescents with Mild to Moderate COVID-19. Available online: https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/outpatient-covid-19-management-strategies-in-children-and-adolescents/ (accessed on 1 January 2022).
- COVID-19 in Children and the Role of School Settings in Transmission—Second Update. Available online: https://www.ecdc.europa.eu/en/publications-data/children-and-school-settings-covid-19-transmission (accessed on 1 January 2002).
- Cotugno, N.; Ruggiero, A.; Bonfante, F.; Petrara, M.R.; Zicari, S.; Pascucci, G.R.; Zangari, P.; De Ioris, M.A.; Santilli, V.; Manno, E.; et al. Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies. Cell Rep. 2021, 34, 108852. [Google Scholar] [CrossRef] [PubMed]
- Lanari, M.; Venturini, E.; Pierantoni, L.; Stera, G.; Gattinara, G.C.; Esposito, S.M.R.; Favilli, S.; Franzoni, E.; Fusco, E.; Lionetti, P.; et al. Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: An Italian inter-society consensus statement. Ital. J. Pediatr. 2022, 48, 7. [Google Scholar] [CrossRef] [PubMed]
- Ameratunga, R.; Longhurst, H.; Steele, R.; Lehnert, K.; Leung, E.; Brooks, A.E.; Woon, S.-T. Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19. J. Allergy Clin. Immunol. Pract. 2021, 9, 3575–3583. [Google Scholar] [CrossRef]
- Rodriguez-Gonzalez, M.; Castellano-Martinez, A.; Cascales-Poyatos, H.M.; Perez-Reviriego, A.A. Cardiovascular impact of COVID-19 with a focus on children: A systematic review. World J. Clin. Cases 2020, 8, 5250–5283. [Google Scholar] [CrossRef] [PubMed]
- Williams, T.S.; Deotto, A.; Roberts, S.D.; Ford, M.K.; Désiré, N.; Cunningham, S. COVID-19 mental health impact among children with early brain injury and associated conditions. Child Neuropsychol. 2021, 15, 1–22. [Google Scholar] [CrossRef]
Type of mAb | n < 12 y | n > 12 y |
---|---|---|
Casirivimab-imdevimab | 24 | 22 |
Bamlanivimab/etesevimab | 9 | 14 |
Sotrovimab 500 mg | 4 | |
Total | 37 | 36 |
Type of comorbidity | n | |
Secondary immunodeficiency | 16 | |
Congenital heart disease | 14 | |
Primary immunodeficiency | 8 | |
Neurodevelopmental disorders | 16 | |
Obesity | 5 | |
Chronic boncopneumopathy | 5 | |
Heart transplant | 3 | |
Newborn | 1 | |
Acquired heart disease | 1 | |
Chronic kidney failure | 1 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Romani, L.; Calò Carducci, F.I.; Chiurchiù, S.; Cursi, L.; De Luca, M.; Di Giuseppe, M.; Krzysztofiak, A.; Lancella, L.; Palma, P.; Vallesi, L.; et al. Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection. Children 2022, 9, 369. https://doi.org/10.3390/children9030369
Romani L, Calò Carducci FI, Chiurchiù S, Cursi L, De Luca M, Di Giuseppe M, Krzysztofiak A, Lancella L, Palma P, Vallesi L, et al. Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection. Children. 2022; 9(3):369. https://doi.org/10.3390/children9030369
Chicago/Turabian StyleRomani, Lorenza, Francesca Ippolita Calò Carducci, Sara Chiurchiù, Laura Cursi, Maia De Luca, Martina Di Giuseppe, Andrzej Krzysztofiak, Laura Lancella, Paolo Palma, Leonardo Vallesi, and et al. 2022. "Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection" Children 9, no. 3: 369. https://doi.org/10.3390/children9030369
APA StyleRomani, L., Calò Carducci, F. I., Chiurchiù, S., Cursi, L., De Luca, M., Di Giuseppe, M., Krzysztofiak, A., Lancella, L., Palma, P., Vallesi, L., Corsetti, T., Campana, A., Nicastri, E., Rossi, P., & Bernardi, S. (2022). Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection. Children, 9(3), 369. https://doi.org/10.3390/children9030369